Mark Robertson-Tessi
Overview
Explore the profile of Mark Robertson-Tessi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
875
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metts J, Aye J, Crane J, Oberoi S, Balis F, Bhatia S, et al.
Cancer
. 2024 Jun;
130(22):3785-3796.
PMID: 38941509
Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements...
2.
Reed D, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, ODonohue T, et al.
J Clin Oncol
. 2024 Jun;
42(25):2955-2960.
PMID: 38843482
ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.
3.
Strobl M, Martin A, West J, Gallaher J, Robertson-Tessi M, Gatenby R, et al.
Cell Syst
. 2024 May;
15(6):510-525.e6.
PMID: 38772367
Toxicity and emerging drug resistance pose important challenges in poly-adenosine ribose polymerase inhibitor (PARPi) maintenance therapy of ovarian cancer. We propose that adaptive therapy, which dynamically reduces treatment based on...
4.
West J, Rentzeperis F, Adam C, Bravo R, Luddy K, Robertson-Tessi M, et al.
Front Immunol
. 2024 Mar;
15:1323319.
PMID: 38426105
Introduction: Metabolism plays a complex role in the evolution of cancerous tumors, including inducing a multifaceted effect on the immune system to aid immune escape. Immune escape is, by definition,...
5.
Welch D, Fridley B, Cen L, Teer J, Yoder S, Pettersson F, et al.
Sci Rep
. 2023 Nov;
13(1):20125.
PMID: 37978271
Osteosarcoma is the most common bone sarcoma in children and young adults. While universally delivered, chemotherapy only benefits roughly half of patients with localized disease. Increasingly, intratumoral heterogeneity is recognized...
6.
Gatenbee C, Baker A, Prabhakaran S, Swinyard O, Slebos R, Mandal G, et al.
Nat Commun
. 2023 Jul;
14(1):4502.
PMID: 37495577
Interest in spatial omics is on the rise, but generation of highly multiplexed images remains challenging, due to cost, expertise, methodical constraints, and access to technology. An alternative approach is...
7.
Gallaher J, Strobl M, West J, Gatenby R, Zhang J, Robertson-Tessi M, et al.
Cancer Res
. 2023 May;
83(16):2775-2789.
PMID: 37205789
Significance: Multiscale mathematical modeling combined with biomarker dynamics during adaptive therapy helps identify underlying features of metastatic cancer to inform treatment decisions.
8.
Strobl M, Martin A, West J, Gallaher J, Robertson-Tessi M, Gatenby R, et al.
bioRxiv
. 2023 Mar;
PMID: 36993591
Toxicity and emerging drug resistance are important challenges in PARP inhibitor (PARPi) treatment of ovarian cancer. Recent research has shown that evolutionary-inspired treatment algorithms which adapt treatment to the tumor's...
9.
West J, Robertson-Tessi M, Anderson A
Trends Cell Biol
. 2022 Nov;
33(4):300-311.
PMID: 36404257
In this opinion, we highlight agent-based modeling as a key tool for exploration of cell-cell and cell-environment interactions that drive cancer progression, therapeutic resistance, and metastasis. These biological phenomena are...
10.
Prabhakaran S, Gatenbee C, Robertson-Tessi M, West J, Beg A, Gray J, et al.
Patterns (N Y)
. 2022 Jul;
3(7):100523.
PMID: 35845830
Understanding the complex ecology of a tumor tissue and the spatiotemporal relationships between its cellular and microenvironment components is becoming a key component of translational research, especially in immuno-oncology. The...